{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:40:37Z","timestamp":1764236437573,"version":"3.46.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"DOI":"10.7759\/cureus.97911","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:37:24Z","timestamp":1764236244000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Outcomes of Darolutamide in Older Patients With Non-metastatic Castration-Resistant Prostate Cancer: A Multi-institutional Comparative Analysis of Efficacy and Tolerability"],"prefix":"10.7759","author":[{"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Hirama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsunemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher HI","year":"2015","unstructured":"Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015, 10:e0139440. 10.1371\/journal.pone.0139440","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi K","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, et al.. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019, 380:1235-46. 10.1056\/NEJMoa1815671","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi K","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al.. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020, 383:1040-9. 10.1056\/NEJMoa2001342","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith MR","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al.. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021, 79:150-8. 10.1016\/j.eururo.2020.08.011","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain M","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, et al.. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378:2465-74. 10.1056\/NEJMoa1800536","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams SC","year":"2023","unstructured":"Williams SC, Mazibuko N, O'Daly O, et al.. Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial. Target Oncol. 2023, 18:403-13. 10.1007\/s11523-023-00959-5","journal-title":"Target Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae019","article-title":"Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS","volume":"29","author":"Shore ND","year":"2024","unstructured":"Shore ND, Gratzke C, Feyerabend S, et al.. Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS. Oncologist. 2024, 29:581-8. 10.1093\/oncolo\/oyae019","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29783","article-title":"Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"7","author":"George DJ","year":"2024","unstructured":"George DJ, Morgans AK, Constantinovici N, et al.. Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. JAMA Netw Open. 2024, 7:e2429783. 10.1001\/jamanetworkopen.2024.29783","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152659","article-title":"Clinical outcomes and prognostic factors in nonmetastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors therapy","volume":"16","author":"Fujiwara R","year":"2024","unstructured":"Fujiwara R, Yamamoto S, Takemura K, et al.. Clinical outcomes and prognostic factors in nonmetastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors therapy. Cancers (Basel). 2024, 16:2659. 10.3390\/cancers16152659","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher HI","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al.. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008, 26:1148-59. 10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf025","article-title":"Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC","volume":"55","author":"Tohi Y","year":"2025","unstructured":"Tohi Y, Kobayashi K, Daizumoto K, et al.. Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. Jpn J Clin Oncol. 2025, 55:643-9. 10.1093\/jjco\/hyaf025","journal-title":"Jpn J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113258","article-title":"Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial","volume":"192","author":"Fizazi K","year":"2023","unstructured":"Fizazi K, Shore ND, Smith M, et al.. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Eur J Cancer. 2023, 192:113258. 10.1016\/j.ejca.2023.113258","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2478167","article-title":"Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage","volume":"21","author":"Ib\u00e1\u00f1ez C","year":"2025","unstructured":"Ib\u00e1\u00f1ez C, Tour\u00eds-Lores M, Montesa \u00c1, et al.. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage. Expert Opin Drug Metab Toxicol. 2025, 21:625-36. 10.1080\/17425255.2025.2478167","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler WP","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, et al.. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019, 25:7448-54. 10.1158\/1078-0432.CCR-19-1050","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433231-real-world-clinical-outcomes-of-darolutamide-in-older-patients-with-non-metastatic-castration-resistant-prostate-cancer-a-multi-institutional-comparative-analysis-of-efficacy-and-tolerability","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:37:24Z","timestamp":1764236244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433231-real-world-clinical-outcomes-of-darolutamide-in-older-patients-with-non-metastatic-castration-resistant-prostate-cancer-a-multi-institutional-comparative-analysis-of-efficacy-and-tolerability"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.97911","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}